Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York. Show more

Location: 345 Park Avenue South, New York, NY, 10010, United States | Website: https://www.protaratx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

124.6M

52 Wk Range

$1.59 - $10.48

Previous Close

$3.23

Open

$3.25

Volume

140,133

Day Range

$3.15 - $3.29

Enterprise Value

6.737M

Cash

122.2M

Avg Qtr Burn

-11.18M

Insider Ownership

2.79%

Institutional Own.

78.73%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.